# EYDIS BIO, INC.: Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | EYDIS BIO, INC. |
| Location | DURHAM, NC |
| Project | Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy |
| Project number | 1R43CA310084-01 |
| Mechanism | R43 |
| Institute | National Cancer Institute |
| Award | $406,496 |
| Awarded | 2026-09-16 |
| Project period | 2026-09-14 to 2027-08-31 |
| UEI | MWWCM7JMBCF1 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11312109). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.